Post Reply
1-20 of 82
HC Surgical acquires majority-stake in LS Lee Surgery for $1.23 million
HC Surgical Specialists is acquiring a majority stake in a clinic for around $1.23 million, so as to broaden the range of medical services that can be offered.
The clinic, LS Lee Surgery, is run by one Dr Lee Lip Seng, a specialist in gallstones, gallbladder, & bile duct surgery.
HCSS, under CEO Dr Heah Sieu Min, focuses on endoscopic procedures.
For the most recent financial year ended June 30 2025, Chirurgia, an entity used by Dr Lee to own LS Lee Surgery, recorded a net profit before tax of some $495,000.
As at June 30, the net tangible asset value and the net asset value of Chirurgia were both $1,241,000.
Following the initial 51% stake, Dr Lee will sell the remaining 49% to HCSS by Nov 30 2029. In the meantime, he will manage Chirurgia for an initial period of ten years starting from April 7.
HCSS shares last traded at 37 cents, up 2.78% year to date.
HC Surgical Specialists earnings up 17.5% to $3.97 mil in 1H2026 from fair value gain on financial assets
HC Surgical Specialists has reported earnings of $3.97 million for the 1HFY2026 ended Nov 30, 2025, up 17.5% y-o-y.
Revenue declined 1.6% y-o-y for 1HFY2026 to $9.78 million, and earnings per share came in 17.7% y-o-y higher at 2.59 cents.
Earnings grew due to non-operational items, including fair value gain on financial assets at fair value through profit or loss of about $910,000, offset by non-existence of fair value loss on derivative financial instruments.
This fair value gain on financial assets was due to the increase in share price of Medinex and Singapore Paincare Holdings partially offset by the decrease in share price of Aoxin Q& M Dental Group.
The group&rsquo s share of results of associates also increased by $98,000 in 1HYFY2026.
The group reported a decrease in other income due to the decrease of grants, decrease in interest income, and non-existence of compensation income. Employee benefits expense also increased for this reporting period due to increased headcount, regular increment and higher locum doctor&rsquo s fees relating to Medistar Services.
The directors are declaring an interim dividend of 0.90 cents per ordinary share.
The group notes that the Ministry of Health recently announced major changes to the Integrated Shield Plan (IP) riders which will take effect from April 1. These new requirements are unlikely to have an immediate material impact on the group&rsquo s financial position, the group says.
HC Surgical Specialists&rsquo FY2025 earnings up by 119.4% y-o-y to $8.4 mil
Catalist-listed HC Surgical Specialists has reported earnings of $8.4 million for the FY2025 ended May 31, 119.4% higher than the $3.9 million posted in FY2024.
Earnings per share (EPS) surged by 117% y-o-y to 5.49 cents, from 2.53 cents previously.
The group&rsquo s earnings surge was attributed to higher non-operational items including a fair value gain on derivative financial instruments of around $1.46 million compared to a fair value loss of $0.62 million last year. The higher bottomline was also due to a fair value gain on financial assets at fair value through profit or loss of approximately $0.7 million from $0.17 million last year, as well as lower income tax expense of approximately $21,000 due to over provision of income tax in prior financial years stemming from the tax rebate announced by the government.
In contrast, revenue for the year inched up by 1.6% y-o-y to $19.1 million mainly due to higher contributions from a new subsidiary acquired during the financial year.
However, profit for the period increased by 73.9% y-o-y to $8.8 million due to higher other items of income, lower expenses and share of profits from the group&rsquo s associates and joint ventures.
Due to the higher earnings, a higher final dividend of 1.18 cents has been proposed, up from 0.7 cents per share last year. This year&rsquo s final dividend brings the group&rsquo s total FY2025 dividend to 1.98 cents per share. The record date will be announced at a later date shareholders will have to approve the final dividend at the group&rsquo s upcoming annual general meeting (AGM) in September.
HC Surgical Specialists
HC Surgical Specialists : 1B1 0% repurchased 330,000 shares at an average price of S$0.29 apiece. This was the first time since May 2021 that the Catalist-listed medical services group has bought back its shares.
In January, HC Surgical Specialists reported that its first-half FY2025 (ended Nov 30) revenue increased 3.4 per cent, and attributable net profit declined 2.1 per cent from H1 FY2024. Chief executive officer Heah Sieu Min highlighted that the group is continuing to focus on its core competencies and look for expansion opportunities. Dr Heah also noted that the renovation of the Camden Centre, completed in December 2024, optimises the endoscopy centre space and modernises the GP clinic. He added that the consolidation within one premise streamlines healthcare services, ensuring continued quality primary and specialist care for all Singapore residents.
HC Surgical Specialists half-year profit down 2.1% at S$3.4 million
Revenue for the period was up 3.4% to S$9.9 million
Catalist-listed medical services provider HC Surgical Specialists&rsquo : 1B1 0%net profit for the six months ended November 2024 was down 2.1 per cent at S$3.4 million, from S$3.5 million the year before.
The drop in profit came mainly from non-operational items, including fair-value loss on derivative financial instruments and the loss from disposal of an associate, said the company in a filing after the market closed on Tuesday (Jan 14).
Revenue for the period was up 3.4 per cent at S$9.9 million from S$9.6 million.
Earnings per share stood at S$0.022, down 3.9 per cent from S$0.0229.
The directors declared an interim dividend of S$0.008 a share, payable on Mar 13.
HC Surgical Specialists&rsquo chief executive officer Dr Heah Sieu Min noted an improved half-year revenue from last year.
&ldquo We will continue to focus on our core competencies and look for opportunities for expansion,&rdquo he said.
The group highlighted that its endoscopy and general practitioner centres, located jointly in Camden Centre, underwent renovation in October 2024 and are now back in operation.
HC Surgical Specialists complete acquisition of two subsidiaries, and acquires more equity interest in former associate
HC Surgical Specialists (HCSS) has completed the acquisition of remaining 49% equity interest in GMH Endoscopy & Surgery, remaining 20% equity interest in HC Ming, and additional 45% equity interest in Medistar Services.
These acquisitions all happened during the six month financial period ended Nov 30, 2024.
On Sept 3, 2024, HCSS acquired the remaining 49% of the total issued and paid-up share capital of its subsidiary, GMH Endoscopy & Surgery for a cash consideration of $636,000.
Based on the audited accounts of GMH as at 31 May 2024, the net asset value of the shares acquired was negative $66,000.
On Oct 30, 2024, HCSS acquired the remaining 20% of the total issued and paid-up share capital of its subsidiary, HC (Ming) for a cash consideration of $2.
Based on the audited accounts of HCMC as at May 31, 2024, the net asset value of the shares acquired was negative $55,000.
HCSS also acquired an additional 45% of the total issued and paid up share capital of Medistar Services on Sept 16, 2024, the company&rsquo s former associate, in connection with the exercise of the forward purchase contract.
The cash consideration for the additional acquisition amounted to approximately $89,000. Following the acquisition, MDS became a 70% owned subsidiary of HCSS.
Based on the audited accounts of MDS as at May 31, 2024, the net asset value of the shares acquired was $42,000.
HC Surgical Specialists earnings up 68.3% y-o-y to $3.5 mil
HC Surgical Specialists (HCSS) 1B1 0.00% has reported earnings at $3.5 million for its 1HFY2024 ended Nov 30, a 68.3% increase from its $2.1 million earnings in the same period last year, after booking fair value gains on its investments in other listed companies.
For the same period, earnings per share rose 65.9% to 2.29 cents from 1.38 cents in 1HFY2023, while revenue fell 4.9% y-o-y to $9.6 million from $10.1 million.
Gross profit in 1HFY2024 also decreased by 8.50% y-o-y, mainly due to an increase in the cost of inventories, consumables and surgery expenses.
Despite the revenue drop, the company&rsquo s fair value gains on financial assets of $0.8 million in 1HFY2024 compared to its fair value losses of $0.9 million in 1HFY2023 contributed to its earnings increase.
HCSS holds a direct interest in Medinex OTX 0.00% , Singapore Paincare Holdings FRQ -0.65% and Aoxin, shareholdings of 22.66%, 2.44% and 0.34%, respectively.
As at Nov 30, the company&rsquo s cash and cash equivalents stood at $6.5 million.
An interim dividend of 0.7 cents per ordinary share has been recommended for 1HFY2024, payable on March 13.
HC Surgical Specialists reports another year of lower earnings at $2.8 million for FY2023
HC Surgical Specialists (HCSS) has reported another year of lower earnings at $2.8 million for its FY2023 ended May 31, a 56.3% decrease from FY2022, as it booked losses from its investments in other listed companies.
Earnings per share fell 56.3% to 1.87 cents from 4.28 cents the previous year, while revenue fell 1.2% to $19.08 million from $19.31 million in FY2022.
This is due to non-operational losses, amounting to $3.5 million as compared to non-operational gains of $0.3 million in FY2022.
The group&rsquo s fair value loss on financial assets amounted to $1.74 million, due to the decrease in share prices of three other listed companies, Medinex, Singapore Paincare Holdings and Aoxin, with which it holds a direct interest of 22.66%, 3.31% and 0.34% respectively.
The directors are recommending a final dividend of 1 Singapore cents, subject to shareholders&rsquo approval at the forthcoming Annual General Meeting to be convened.
Prior to this, the group has already paid an interim dividend of 1 Singapore cents per share in March 2023. In aggregate, the total dividend for FY2023 amounts to 2 Singapore cents per share.
The group will have its first orthopaedic specialist joining in June 2023, which is &ldquo an important first step to broaden the spectrum of the group&rsquo s medical services&rdquo .
Only 10,000 shares traded which equates to approx. $4,000 value. Such little volume, unlikely.
ozone2002 ( Date: 25-Oct-2022 13:37) Posted:
|
0.45 
+0.125
climbed 38% today, news of privatisation?
+0.125climbed 38% today, news of privatisation?
HC Surgical Specialists posts 7.2% fall in H1 net profit to S$4.6m
CATALIST-LISTED HC Surgical Specialists&rsquo $ HC Surgical: 1B1 0% net profit slipped 7.2 per cent to S$4.6 million from S$5 million the previous year, in part due to a decline in revenue as fewer patients pursued elective medical treatments amid the heightened Covid-19 situation across the half year ended Nov 30.
Revenue was down 5.2 per cent to S$10.4 million from S$11 million the year before, its unaudited results indicated on Tuesday (Jan 11).
The gastrointestinal medical services specialist clinic group posted a 60.8 per cent gain under other income to S$1.1 million, mainly due to S$86,000 in grants from the Jobs Support Scheme and Rental Support Scheme, higher dividend income from investment on financial assets at fair value through profit or loss of S$283,000 and higher interest income of S$46,000.
It also booked a fair-value gain of S$689,000 on financial assets at fair value through profit or loss. This was attributed to the increase in the share prices of Medinex and Singapore Paincare Holdings, both of which the group has a direct interest in, as well as a fair-value gain on Acumen Holdings.
Earnings per share in the period came to 3.12 Singapore cents, against 3.32 cents previously. Net asset value was 5.84 Singapore cents a share, compared with 6.60 cents as at May 31, 2021.
The board has recommended an interim dividend of 1.40 Singapore cents a share, down from 1.70 cents before, to be paid out on Jan 28.
As the pandemic stabilises, HC Surgical Specialists expects business to pick up.
" The Covid-19 pandemic will not be entirely eradicated in the short term, but people will learn to live with Covid-19 and resume most of their daily activities in the next 12 months. The group will remain vigilant and continue to strengthen its core competencies to provide good service to all its patients," it said in a press statement.
HC Surgical Specialists report 7.2% YoY lower earnings of $4.6 mil for the 1HFY2022. Revenue decreased 5.2% YoY to S$10.4 m in HY2022. Declares interim dividend of $0.014 per share (prior yr $0.023)
HC Surgical acquires remaining stake in Jason Lim Endoscopy & Surgery for $9 mil
HC Surgical Specialists (HCSS) will be acquiring the remaining 49% stake in Jason Lim Endoscopy and Surgery (JLES) for $9 million.
Upon completion of the acquisition, HCSS will own 100% of JLES.
The acquisition is in line with the group&rsquo s long-term plans for growth, and will continue to enhance the working relationship with Dr Lim as well as motivate Dr Lim, having commenced his employment with the group since Aug 13, 2018, to further improve the profitability of JLES.
The total purchase consideration of $9.06 million will be satisfied in the form of 80% cash payable over a period of two years and 20% shares in the share capital of the company, which will be issued two years later, at an issue price based on the volume weighted average price of the company' s shares for the full market day on the day immediately prior to the issuance.
Based on the unaudited accounted of JLES for its 12 months ended May 31, 2021, profit before tas was about $1.5 million, while the net tangible asset came in at $1.3 million and net asset value stood at $1.3 million.
CEO of HCSS, Dr Heah Sieu Min says: &ldquo Dr Lim is a talented specialist who has proven to be very popular with patients, and is a fast learner in terms of growing his business and management skills. We are excited to be part of his growth journey as we fortify our relationship with Dr Lim through this acquisition. We will continue to execute on our corporate strategy in looking out for young talented specialists like Dr Lim, providing them with the necessary support and platform for growth.&rdquo
HC Surgical acquires remaining stake in Jason Lim Endoscopy & Surgery for $9 mil
HC Surgical Specialists (HCSS) will be acquiring the remaining 49% stake in Jason Lim Endoscopy and Surgery (JLES) for $9 million.Upon completion of the acquisition, HCSS will own 100% of JLES.
The acquisition is in line with the group' s long-term plans for growth, and will continue to enhance the working relationship with Dr Lim as well as motivate Dr Lim, having commenced his employment with the group since Aug 13, 2018, to further improve the profitability of JLES.
The total purchase consideration of $9.06 million will be satisfied in the form of 80% cash payable over a period of two years and 20% shares in the share capital of the company, which will be issued two years later, at an issue price based on the volume weighted average price of the company' s shares for the full market day on the day immediately prior to the issuance.
Based on the unaudited accounted of JLES for its 12 months ended May 31, 2021, profit before tas was about $1.5 million, while the net tangible asset came in at $1.3 million and net asset value stood at $1.3 million.
CEO of HCSS, Dr Heah Sieu Min says: " Dr Lim is a talented specialist who has proven to be very popular with patients, and is a fast learner in terms of growing his business and management skills. We are excited to be part of his growth journey as we fortify our relationship with Dr Lim through this acquisition. We will continue to execute on our corporate strategy in looking out for young talented specialists like Dr Lim, providing them with the necessary support and platform for growth."
Shares in HCSS closed at 51 cents on Aug 23.
HC Surgical surges 19% following strong H2 results
Shares of medical services provider HC Surgical Specialists jumped 18.8 per cent or S$0.09 to S$0.57 in early trade on Wednesday, with 225,300 shares changing hands as at 9.29am.No married deals were recorded, according to ShareInvestor data.
The surge comes after the Catalist-listed group on Tuesday announced a 64.7 per cent increase in H2 net profit to S$3 million for the six months ended May 31, as revenue rose 78 per cent to S$12.4 million.
HC Surgical said in a statement that the increase was due to " pent-up demand for its services post circuit-breaker" .
The board has recommended a final dividend of 2.3 cents a share, compared with 0.7 cent previously. This will bring the full-year payout to four cents a share, twice the dividend of two cents paid out for the year before.
As at 9.51am on Wednesday, the counter was trading at 54.5 Singapore cents, up 6.5 cents or 13.5 per cent.
HC Surgical Specialists H2 earnings up by 64.7% on pent-up demand for gut checks
CATALIST-LISTED medical services provider HC Surgical Specialists has doubled its dividend, citing uplift from demand for colorectal procedures.
Second-half net profit was up by 64.7 per cent year on year to S$3.0 million for the six months to May 31, 2021, according to unaudited financial statements released on Tuesday.
That' s as revenue rose 78.0 per cent to S$12.4 million, which the group attributed to an increase in patients after the end of the year-ago " circuit breaker" semi-lockdown.
Earnings per share stood at 2.02 Singapore cents for the half-year, up from 1.21 cents before. Net asset value was 6.6 cents a share, against 10.81 cents as at May 31, 2020.
For the 12 months, net profit more than doubled from S$3.99 million to S$8.0 million, while revenue increased by 39.7 per cent year on year to S$23.4 million.
The higher group revenue was " due to the pent-up demand for its services post circuit breaker" , HC Surgical said in a statement.
The board recommended a final dividend of 2.3 cents a share, compared with 0.7 cent previously. If approved, it would take the full-year payout to 4.0 cents a share, twice the dividend of 2.0 cents paid out for the year before.
Books closure and payment dates will be announced later, added the group, which offers colorectal-focused endoscopic procedures across 18 clinics.
HC Surgical Specialists H2 earnings up by 64.7% on pent-up demand for gut checks
Catalist-listed medical services provider HC Surgical Specialists has doubled its dividend, citing uplift from demand for colorectal procedures.Second-half net profit was up by 64.7 per cent year on year to S$3.0 million for the six months to May 31, 2021, according to unaudited financial statements released on Tuesday.
That' s as revenue rose 78.0 per cent to S$12.4 million, which the group attributed to an increase in patients after the end of the year-ago " circuit breaker" semi-lockdown.
Earnings per share stood at 2.02 Singapore cents for the half-year, up from 1.21 cents before. Net asset value was 6.6 cents a share, against 10.81 cents as at May 31, 2020.
For the 12 months, net profit more than doubled from S$3.99 million to S$8.0 million, while revenue increased by 39.7 per cent year on year to S$23.4 million.
The higher group revenue was " due to the pent-up demand for its services post circuit breaker" , HC Surgical said in a statement.
The board recommended a final dividend of 2.3 cents a share, compared with 0.7 cent previously. If approved, it would take the full-year payout to 4.0 cents a share, twice the dividend of 2.0 cents paid out for the year before.
Books closure and payment dates will be announced later, added the group, which offers colorectal-focused endoscopic procedures across 18 clinics.
Shares closed on Tuesday at S$0.48, down by half a cent or 1.03 per cent, before the results were announced.
Under the radar stock that was not covered by analyst
U can have an edge against these analyst by uncovering undervalued gems
gd luck dyodd
U can have an edge against these analyst by uncovering undervalued gems
gd luck dyodd
ozone2002 ( Date: 14-Jan-2021 09:17) Posted:
|
HC Surgical Specialists reports H1 net profit of S$5m, buoyed by fair-value gain
CATALIST-LISTED HC Surgical Specialists more than doubled its earnings in the first half-year, buoyed by a fair-value gain, its unaudited results indicated on Wednesday.
Net profit rose to S$5 million for the six months to Nov 30, 2020, up from S$2.17 million before revenue was up by 12.4 per cent year on year, to S$10.99 million.
The colorectal clinic operator booked a fair-value gain of S$1.54 million on financial assets at fair value through profit or loss, reversing an earlier S$601,000 loss.
This was attributed to an increase in the share price of medical support services provider Medinex, of which HC Surgical Specialists holds an effective stake of 32.4 per cent, and an increase in the fair value of its investment in Singapore Paincare Holdings, which was publicly listed last July.
Besides the fair-value gain, the medical-services group notched a rise in turnover on a higher volume of patients from mid-2020, after the two-month quasi-lockdown or " circuit breaker" imposed by the government to contain the Covid-19 outbreak.
HC Surgical Specialists said in a statement that its foreign patient volumes have fallen amid the pandemic, but " the group has not suffered much impact as we are able to rely on the local population demand" .
Still, the group also warned that, while it has seen pent-up demand for its services post-circuit breaker, " it is uncertain if this trend will continue" .
" With the Covid-19 situation still raging globally and the slowdown of economic activity, both local and worldwide, the group is mindful to keep its operations intact and will continue to strengthen its core competencies," it said.
Earnings per share came to 3.32 Singapore cents, against 1.45 Singapore cents previously. Net asset value was 13.33 Singapore cents a share, compared with 10.81 Singapore cents as at May 31, 2020.
The board recommended an interim dividend of 1.7 Singapore cents a share, up from 1.3 Singapore cents before, to be paid on Feb 2. The books close on Jan 21.
Last:0.435 +0.085
Chiong ah!
know how to spot the right stocks and wait for market to realise its potential
gs luck dyodd
+0.085Chiong ah!
know how to spot the right stocks and wait for market to realise its potential
gs luck dyodd
ozone2002 ( Date: 14-Jun-2020 20:16) Posted:
|